SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN)
CAPS Rating:
A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.
A biopharmaceutical company, which is engaged in the development and commercialization of novel therapeutics to treat life-threatening diseases.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
Recs
Putting a quality sells team in place in China to market it current product. This will allow them to expand on their already successful Zaxadin medication and they will be in place for their new products and could possibly market other newly approved meds.